Citation Impact
Citing Papers
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment
2014
Genome-wide CRISPR screens reveal a specific ligand for the glycan-binding immune checkpoint receptor Siglec-7
2021 StandoutNobel
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013
Current knowledge on exosome biogenesis and release
2017 Standout
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
2013 Standout
Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
2018 Standout
Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo
1999
Aptide-conjugated liposome targeting tumor-associated fibronectin for glioma therapy
2013
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma
2008
The tenascin family of ECM glycoproteins: Structure, function, and regulation during embryonic development and tissue remodeling
2000
FOXP3+ regulatory T cells: control of FOXP3 expression by pharmacological agents
2011 StandoutNobel
Synthetic glycobiology: exploits in the Golgi compartment
2006 StandoutNobel
Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology
2013 Standout
Treatment of intracranial human glioblastoma by direct intratumoral administration of 131I‐labelled anti‐tenascin monoclonal antibody BC‐2
1992
Tumor Suppressor microRNAs Contribute to the Regulation of PD-L1 Expression in Malignant Pleural Mesothelioma
2017
Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes
2009
Tumor-infiltrating lymphocytes, forkhead box P3, programmed death ligand-1, and cytotoxic T lymphocyte–associated antigen-4 expressions before and after neoadjuvant chemoradiation in rectal cancer
2015
Phage antibodies with pan-species recognition of the oncofoetal angiogenesis marker fibronectin ED-B domain
1996 StandoutNobel
Tumor immunoediting and immunosculpting pathways to cancer progression
2007
Activation and regulation of the inflammasomes
2013 Standout
NLRP12 Suppresses Colon Inflammation and Tumorigenesis through the Negative Regulation of Noncanonical NF-κB Signaling
2012
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
Checkpoint inhibitor-induced uveitis: a case series
2017
The immune contexture in cancer prognosis and treatment
2017 Standout
Molecular variants of fibronectin and laminin: structure, physiological occurrence and histopathological aspects
1996
Genes other than BRCA1 and BRCA2 involved in breast cancer susceptibility
2002
Modulation of Cell Cycle Components by Epigenetic and Genetic Events
2005
Exosomes as Biomarker Enriched Microvesicles: Characterization of Exosomal Proteins Derived from a Panel of Prostate Cell Lines with Distinct AR Phenotypes
2012
Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues
1992
Differential expression of the fibronectin isoform containing the ED-B oncofetal domain in normal human fibroblast cell lines originating from different tissues
1992
Epigenetics in cancer
2009 Standout
Putting tumours in context
2001 Standout
RB and cell cycle progression
2006 Standout
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2017 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Extracellular matrix structure
2015 Standout
Inflammasomes in carcinogenesis and anticancer immune responses
2012
Epigenetic Silencing of the p16 Tumor Suppressor Is Associated with Loss of CTCF Binding and a Chromatin Boundary
2009
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Male breast cancer
2006 Standout
Remodelling the extracellular matrix in development and disease
2014 Standout
Endocrine side effects of cancer immunotherapy
2017
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis
1995
Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β2‐microglobulin inactivation in MSI‐positive tumors and LMP7/TAP2 downregulation in MSI‐negative tumors
2003
Identification of a Glioblastoma-Associated Tenascin-C Isoform by a High Affinity Recombinant Antibody
1999 StandoutNobel
Death and anti-death: tumour resistance to apoptosis
2002 Standout
Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy
2017 Standout
Intestinal epithelial cells: regulators of barrier function and immune homeostasis
2014 Standout
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
2005
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
2015
HLA-G Molecules: from Maternal–Fetal Tolerance to Tissue Acceptance
2003
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance
2015
Tumor Hypoxia: Definitions and Current Clinical, Biologic, and Molecular Aspects
2001 Standout
In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells
2003 Standout
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations
2018
Gingival Fibroblasts as a Promising Source of Induced Pluripotent Stem Cells
2010 StandoutNobel
Chemokines, cytokines and exosomes help tumors to shape inflammatory microenvironment
2016
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Drug Resistance and the Solid Tumor Microenvironment
2007 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Tremelimumab (CP-675,206), a Cytotoxic T Lymphocyte–Associated Antigen 4 Blocking Monoclonal Antibody in Clinical Development for Patients with Cancer
2007
Human Leukocyte Antigen-G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells
2007 Standout
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma
2013 StandoutNobel
Phage antibodies with pan‐species recognition of the oncofoetal angiogenesis marker fibronectin ED‐B domain
1996 StandoutNobel
Pituitary Expression of CTLA-4 Mediates Hypophysitis Secondary to Administration of CTLA-4 Blocking Antibody
2014
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Engineering Craniofacial Structures: Facing the Challenge
2009
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
2008 StandoutNobel
Breast Cancer Treatment
2019 Standout
Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
2018 StandoutNobel
Endocrinological side-effects of immune checkpoint inhibitors
2016
Fibronectin at a glance
2002 Standout
Colon Immune-Related Adverse Events: Anti-CTLA-4 and Anti-PD-1 Blockade Induce Distinct Immunopathological Entities
2017
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
2015 Standout
The Fibronectin Domain ED-A Is Crucial for Myofibroblastic Phenotype Induction by Transforming Growth Factor-β1
1998 Standout
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Neoantigens in cancer immunotherapy
2015 StandoutScience
CCR9/CCL25 expression in non-small cell lung cancer correlates with aggressive disease and mediates key steps of metastasis
2014
Immune Checkpoint Blockade in Cancer Therapy
2015 Standout
Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity
2017 StandoutNobel
Anti–Cytotoxic T-Lymphocyte Antigen-4 Antibody: The First in an Emerging Class of Immunomodulatory Antibodies for Cancer Treatment
2008
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
2018 Standout
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Sandra Salvi being referenced
Role of CXCL13-CXCR5 Crosstalk Between Malignant Neuroblastoma Cells and Schwannian Stromal Cells in Neuroblastic Tumors
2011
Recruitment of a Host's Osteoprogenitor Cells Using Exogenous Mesenchymal Stem Cells Seeded on Porous Ceramic
2009
The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production
2013
Delineation of HER2 Gene Status in Breast Carcinoma by Silver in Situ Hybridization is Reproducible among Laboratories and Pathologists
2008
Heterogeneous nuclear ribonucleoprotein K: altered pattern of expression associated with diagnosis and prognosis of prostate cancer
2009
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction
2005
Biochemical analysis of HLA class I subunits expression in breast cancer tissues
2000
Analysis of HLA-G expression in breast cancer tissues
2002
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
2012
Expression of tenascin and of the ED-B containing oncofetal fibronectin isoform in human cancer
1990
Interleukin (IL)‐18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor
2010
Investigation of HLA class I downregulation in breast cancer by RT-PCR
2001
p16INK4a promoter methylation and protein expression in breast fibroadenoma and carcinoma
2004
Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma.
2014